Theratechnologies posts new tesamorelin data
October 26, 2009 by leonardzehr · Leave a Comment
Montreal-based Theratechnologies (TSX:TH) presented additional data about its lead tesamorelin drug to treat excess abdominal fat in HIV patients with lipodystrophy at an HIV conference in Philadelphia. In a statement, the company said results indicated that after 26 weeks of treatment the 543 patients treated with 2 mille-grams daily of tesamorelin reported “clinically relevant improvements [...]
Listen to BioTuesdays 
